Why the study?
Does antithrombotic therapy prevent thromboembolic and obstetric complications in pregnant patients with genetic thrombophilia?
Does antithrombotic therapy prevent thromboembolic and obstetric complications in pregnant patients with genetic thrombophilia?
Antithrombotic therapy is recommended before, during, and after pregnancy for patients with confirmed genetic thrombophilia to prevent thromboembolic and obstetric complications.
Answers are grounded in this paper and cite their sources.
Reinforces peripartum antithrombotic recommendations in genetic thrombophilia; leaves open need for RCTs to confirm benefit.
Genetic thrombophilia is a risk factor for both thromboembolic and obstetric complications. Patients with a family history of thrombotic and obstetric complications should be examined for the presence of thrombophilia. If a hemostasis problem is confirmed, antithrombotic therapy is recommended to be initiated at early stages of pregnancy. Moreover, this therapy is better to be started at the stage of preparation for pregnancy and continued throughout the pregnancy and during the postpartum period to avoid thromboembolic and obstetrical complications.
No takes yet. Share an insight, caveat, or question.
Kapanadze et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: